Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

579
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
579
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

610
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
610
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.5K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

JAMA·2026
Same author

Patient Perspectives on Cardiac Gene Therapy: A Survey of Knowledge, Attitudes, and Educational Needs.

Journal of cardiac failure·2026
Same author

Cardiology Provider Knowledge and Attitudes Toward Cardiac Gene Therapy: A Multi-Institutional National Survey.

JACC. Heart failure·2026
Same author

Angiotensin-Neprilysin Inhibition and Renal Outcome in Men and Women With Heart Failure.

Journal of the American Heart Association·2026
Same author

Finerenone and polypharmacy in heart failure with mildly reduced or preserved ejection fraction: a marker of risk, not a barrier to therapy.

European journal of heart failure·2026
Same author

Health status trajectories using Markov modeling in patients with heart failure with preserved ejection fraction.

Revista espanola de cardiologia (English ed.)·2026
Same journal

Five-year outcomes of glucagon-like peptide-1 agonists in hypertrophic cardiomyopathy: A population-based retrospective study.

Journal of cardiology·2026
Same journal

Transitional Care for Pediatric Cardiomyopathy Patients in Japan: A Nationwide Survey of Current Practices and Challenges.

Journal of cardiology·2026
Same journal

Neutrophil-to-lymphocyte ratio in patients with low-flow aortic stenosis undergoing transcatheter aortic valve implantation.

Journal of cardiology·2026
Same journal

Cardiovascular and limb outcomes with SGLT2 inhibitors in patients with diabetes following peripheral endovascular therapy.

Journal of cardiology·2026
Same journal

Integrated interpretation of exercise electrocardiography and cardiopulmonary exercise testing for detection of significant coronary artery stenosis.

Journal of cardiology·2026
Same journal

Author's reply to "Comment on 'Cardio-ankle vascular index as a screening tool for coronary artery disease in patients with metabolic dysfunction-associated steatotic liver disease'".

Journal of cardiology·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.5K

Gene therapy for heart failure.

Barry Greenberg1

  • 1Advanced Heart Failure Treatment Program, University of California, San Diego, CA, USA.

Journal of Cardiology
|March 31, 2015
PubMed
Summary
This summary is machine-generated.

Gene transfer therapy using adeno-associated virus (AAV) delivering SERCA2a showed promising results for heart failure patients. This novel treatment reduced cardiovascular events and improved cardiac function with no safety concerns.

Keywords:
Adeno-associated virusCa(2+)ATPase (SERCA2a)Gene transfer therapyHeart failureSarco(endo)plasmic reticulum

More Related Videos

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.4K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.4K

Related Experiment Videos

Last Updated: Apr 15, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.5K
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.4K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.4K

Area of Science:

  • Cardiology
  • Gene Therapy
  • Molecular Medicine

Background:

  • Heart failure is a global health concern with high morbidity and mortality.
  • Current treatments for heart failure remain insufficient.
  • Gene transfer offers a novel therapeutic strategy for cardiac dysfunction.

Purpose of the Study:

  • To evaluate the safety and efficacy of adeno-associated virus-mediated gene transfer of SERCA2a in patients with advanced heart failure.
  • To determine the optimal dose of AAV/SERCA2a for treating systolic heart failure.

Main Methods:

  • The Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) study was a Phase 2a, double-blind, randomized, placebo-controlled trial.
  • Patients received direct antegrade infusion of AAV/SERCA2a or placebo into the coronary circulation.
  • Dose-finding was performed, with high-dose therapy at 1×10(13) DNase Resistant Particles.

Main Results:

  • High-dose AAV/SERCA2a therapy demonstrated favorable changes in clinically relevant domains compared to placebo at 12 months.
  • A significant reduction in cardiovascular events was observed in the AAV/SERCA2a group, persisting through 36 months.
  • Sustained transgene expression was detected in myocardial tissue up to 31 months post-delivery, with no safety concerns identified.

Conclusions:

  • AAV/SERCA2a gene therapy is a safe and potentially effective treatment for advanced systolic heart failure.
  • This approach offers a promising new avenue for managing heart failure by targeting intracellular calcium handling.
  • Further investigation in Phase 2b (CUPID 2) and other studies is warranted to confirm these findings.